UBS analyst Kevin Caliendo raised the firm’s price target on Quest Diagnostics (DGX) to $190 from $180 and keeps a Neutral rating on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DGX:
- Quest Diagnostics price target raised to $210 from $190 at Mizuho
- Quest Diagnostics price target raised to $195 from $192 at Truist
- Quest Diagnostics price target raised to $190 from $185 at Evercore ISI
- Quest Diagnostics price target raised to $190 from $185 at Barclays
- Guardant Health, Quest Diagnostics announce blood-based screening test pact